[Federal Register Volume 64, Number 222 (Thursday, November 18, 1999)]
[Notices]
[Pages 63050-63051]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 99-30067]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by agencies of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of federally-funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for companies and may also be available for licensing.
[[Page 63051]]
ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by writing to the indicated
licensing contact at the Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A
signed Confidential Disclosure Agreement will be required to receive
copies of the patent applications.
Methods of Inhibiting Cancer Cells With ADNF III Antisense
Oligonucleotides
I Gozes, R Zamostiano, E Gelber, A Pinhasov, M Bassan (all of Tel Aviv
University), DE Brenneman (NICHD)
Serial No.: 09/364,609 filed 30 Jul 1999.
Licensing Contact: Susan S. Rucker; 301/496-7056 ext. 245; e-mail:
sr156v@nih.gov.
This application describes methods of inhibiting the proliferation
of cells using an antisense oligonucleotide derived from the
polypeptide Activity Dependent Neurotrophic Factor III (ADNF III)/
Activity Dependent Neuroprotective Protein (ADNP). Preferred antisense
oligonucleotides are complementary to the 5' region of ADNF III/ADNP.
The ability of such antisense oligonucleotides to inhibit cell
proliferation has been demonstrated in in vitro models such as the HT29
colon cancer cell line. Based on the location of ADNF III/ADNP on
chromosome 20 at 20q13, a region which has been shown via CGH to be
associated with breast, ovary, colon, head and neck, brain and
pancreatic cancers, ADNF III/ADNP antisense molecules might also be
expected to be useful in treating one or more of these cancers.
Orally Active Peptides That Prevent Cell Damage and Death
DE Brenneman, CY Spong (both of NICHD), I Gozes, A Pinhasov, E Giladi
(all of Tel Aviv University)
Serial No.: 60/149,956 filed 18 Aug. 1999.
Licensing Contact: Susan S. Rucker; 301/496-7056 ext. 245; e-mail:
sr156v@nih.gov.
This application describes two peptides which are orally active and
which have been shown in in vitro assays to protect against neuronal
cell death. In animal model systems for Alzheimer's disease and Fetal
Alcohol Syndrome the peptide have also been demonstrated to be useful.
The first peptide is D-SAL, a D-isomer of the peptide SAL (SALLRSIPA)
derived from Activity Dependent Neurotrophic Factor I (ADNF I). The
second peptide is D-NAP, a D-isomer of the peptide NAP (NAPVSIPQ)
derived from a related protein Activity Dependent Neuroprotective
Protein (ADNP)/Activity Dependent Neurotrophic Factor III (ADNF III).
The peptides may be used alone or in combination. The peptides may be
constructed solely of D-isomers of their amino acids or combinations of
D and L amino acids. Other diseases involving neuronal cell death where
D-SAL or D-NAP may be useful include Huntington's disease, epilepsy,
Parkinson's disease and Tourette's syndrome.
Dated: November 9, 1999.
Jack Spiegel,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer.
[FR Doc. 99-30067 Filed 11-17-99; 8:45 am]
BILLING CODE 4140-01-P
